228. 閉塞性細気管支炎 Bronchiolitis obliterans Clinical trials / Disease details
臨床試験数 : 96 / 薬物数 : 125 - (DrugBank : 34) / 標的遺伝子数 : 33 - 標的パスウェイ数 : 155
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2014-002022-12-SE (EUCTR) | 06/08/2015 | 15/10/2014 | European Trial of Pirfenidone in BOS (EPOS). | A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial | Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | Clinical Trials Unit, Rigshospitalet | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden | ||
| 2 | EUCTR2014-002022-12-NL (EUCTR) | 13/05/2015 | 03/11/2014 | European Trial of Pirfenidone in BOS (EPOS). | A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial | Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | Clinical Trials Unit, Rigshospitalet | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Belgium;Denmark;Germany;Netherlands;United Kingdom;Sweden | ||
| 3 | EUCTR2014-002022-12-BE (EUCTR) | 10/03/2015 | 15/10/2014 | European Trial of Pirfenidone in BOS (EPOS). | A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial | Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000015490;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | Clinical Trials Unit, Rigshospitalet | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden | ||
| 4 | EUCTR2014-002022-12-GB (EUCTR) | 06/01/2015 | 15/10/2014 | European Trial of Pirfenidone in BOS (EPOS). | A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial | Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | Clinical Trials Unit, Rigshospitalet | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 90 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden | ||
| 5 | EUCTR2014-002022-12-DE (EUCTR) | 30/12/2014 | 21/10/2014 | European Trial of Pirfenidone in BOS (EPOS). | A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial | Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | Clinical Trials Unit, Rigshospitalet | NULL | Not Recruiting | Female: yes Male: yes | 80 | Phase 2 | Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden | ||
| 6 | EUCTR2014-002022-12-DK (EUCTR) | 15/12/2014 | 04/11/2014 | European Trial of Pirfenidone in BOS (EPOS). | A European multi-centre, randomised, double-blind trial of pirfenidone in bronchiolitis-obliterans-syndrome grade 1-3 in lung transplant recipients. - EPOS Trial | Bronchiolitis Obliterans Syndrome (BOS) in patients following lung transplantation. This syndrome occurs due to rejection of the transplanted organ (s). MedDRA version: 20.0;Level: LLT;Classification code 10049202;Term: Bronchiolitis obliterans;System Organ Class: 100000004855;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Esbriet Product Name: Pirfenidone INN or Proposed INN: PIRFENIDONE Other descriptive name: 5-Methyl-1-Phenyl-2-1-(H)-Pyridone | Clinical Trials Unit, Rigshospitalet | NULL | Not Recruiting | Female: yes Male: yes | 90 | Phase 2 | Belgium;Denmark;Netherlands;Germany;United Kingdom;Sweden |